Complement regulator C4BP binds to Staphylococcus aureus and decreases opsonization

Molecular Immunology

Volumn 50, Issue 4, 2012, Pages 253-261

  Hair, Pamela S ^a   Wagner, Sara M ^a   Friederich, Patricia T ^a   Drake, Richard R ^a   Nyalwidhe, Julius O ^a   Cunnion, Kenji M ^a,b,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Children's Specialty Group   (United States)

^c CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

Author keywords

C3 convertase; C4b binding protein; Classical pathway; Complement; Staphylococcus aureus

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BACTERIUM ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4B BINDING PROTEIN;

ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; NONHUMAN; NORMAL HUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; STAPHYLOCOCCUS AUREUS;

ANTIBODIES, BACTERIAL; BLOTTING, WESTERN; COMPLEMENT ACTIVATION; COMPLEMENT C4; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNE EVASION; MASS SPECTROMETRY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

EID: 84858336416     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.01.010     Document Type: Article

References (39)

1. Andre I., Persson J., Blom A.M., Nilsson H., Drakenberg T., Lindahl G., Linse S. Streptococcal M protein: structural studies of the hypervariable region, free and bound to human C4BP. Biochemistry 2006, 45:4559-4568.
2. Barbosa A.S., Abreu P.A., Vasconcellos S.A., Morais Z.M., Goncales A.P., Silva A.S., Daha M.R., Isaac L. Immune evasion of leptospira species by acquisition of human complement regulator C4BP. Infect. Immun. 2009, 77:1137-1143.
3. Berggard K., Lindahl G., Dahlback B., Blom A.M. Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b. Eur. J. Immunol. 2001, 31:2771-2780.
4. Blom A.M., Ram S. Contribution of interactions between complement inhibitor C4b-binding protein and pathogens to their ability to establish infection with particular emphasis on Neisseria gonorrhoeae. Vaccine 2008, 26(Suppl. 8):I49-I55.
5. Blom A.M., Villoutreix B.O., Dahlback B. Functions of human complement inhibitor C4b-binding protein in relation to its structure. Arch. Immunol. Ther. Exp. (Warsz) 2004, 52:83-95.
6. Calhoun J.H., Manring M.M., Shirtliff M. Osteomyelitis of the long bones. Semin. Plast. Surg. 2009, 23:59-72.
7. Cunnion K.M., Buescher E.S., Hair P.S. Serum complement factor I decreases Staphylococcus aureus phagocytosis. J. Lab. Clin. Med. 2005, 146:279-286.
8. Cunnion K.M., Hair P.S., Buescher E.S. Cleavage of complement C3b to iC3b on the surface of Staphylococcus aureus is mediated by serum complement factor I. Infect. Immun. 2004, 72:2858-2863.
9. Cunnion K.M., Lee J.C., Frank M.M. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect. Immun. 2001, 69:6796-6803.
10. Cunnion K.M., Zhang H.M., Frank M.M. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect. Immun. 2003, 71:656-662.
11. Daha M.R., van Es L.A. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. J. Immunol. 1980, 125:2051-2054.
12. Deresinski S., Herrera V. Immunotherapies for Staphylococcus aureus: current challenges and future prospects. Infect. Control. Hosp. Epidemiol. 2010, 31(Suppl. 1):S45-S47.
13. Dieudonne-Vatran A., Krentz S., Blom A.M., Meri S., Henriques-Normark B., Riesbeck K., Albiger B. Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J. Immunol. 2009, 182:7865-7877.
14. Dryden M.S. Skin and soft tissue infection: microbiology and epidemiology. Int. J. Antimicrob. Agents 2009, 34(Suppl. 1):S2-S7.
15. Fry D.E., Barie P.S. The changing face of Staphylococcus aureus: a continuing surgical challenge. Surg. Infect. (Larchmt) 2011, 12:191-203.
16. Fujita T., Gigli I., Nussenzweig V. Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J. Exp. Med. 1978, 148:1044-1051.
17. Gigli I., Fujita T., Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc. Natl. Acad. Sci. U.S.A 1979, 76:6596-6600.
18. Gould I.M., Reilly J., Bunyan D., Walker A. Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control. Clin. Microbiol. Infect. 2010, 16:1721-1728.
19. Grosskinsky S., Schott M., Brenner C., Cutler S.J., Simon M.M., Wallich R. Human complement regulators C4b-binding protein and C1 esterase inhibitor interact with a novel outer surface protein of Borrelia recurrentis. PLoS Negl. Trop. Dis. 2010, 4:e698.
20. Hair P.S., Echague C.G., Sholl A.M., Watkins J.A., Geoghegan J.A., Foster T.J., Cunnion K.M. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect. Immun. 2010, 78:1717-1727.
21. Hair P.S., Ward M.D., Semmes O.J., Foster T.J., Cunnion K.M. Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J. Infect. Dis. 2008, 198:125-133.
22. Hallstrom T., Jarva H., Riesbeck K., Blom A.M. Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J. Immunol. 2007, 178:6359-6366.
23. Jarva H., Ram S., Vogel U., Blom A.M., Meri S. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J. Immunol. 2005, 174:6299-6307.
24. Jenkins H.T., Mark L., Ball G., Persson J., Lindahl G., Uhrin D., Blom A.M., Barlow P.N. Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor. J. Biol. Chem. 2006, 281:3690-3697.
25. Jongerius I., Kohl J., Pandey M.K., Ruyken M., van Kessel K.P., van Strijp J.A., Rooijakkers S.H. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 2007, 204:2461-2471.
26. Kirjavainen V., Jarva H., Biedzka-Sarek M., Blom A.M., Skurnik M., Meri S. Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog. 2008, 4:e1000140.
27. Nordstrom T., Blom A.M., Forsgren A., Riesbeck K. The emerging pathogen Moraxella catarrhalis interacts with complement inhibitor C4b binding protein through ubiquitous surface proteins A1 and A2. J. Immunol. 2004, 173:4598-4606.
28. Perez-Roth E., Alcoba-Florez J., Lopez-Aguilar C., Gutierrez-Gonzalez I., Rivero-Perez B., Mendez-Alvarez S. Familial furunculosis associated with community-acquired leukocidin-positive methicillin-susceptible Staphylococcus aureus ST152. J. Clin. Microbiol. 2010, 48:329-332.
29. Pietikainen J., Meri T., Blom A.M., Meri S. Binding of the complement inhibitor C4b-binding protein to Lyme disease Borreliae. Mol. Immunol. 2010, 47:1299-1305.
30. Portoles M., Kiser K.B., Bhasin N., Chan K.H., Lee J.C. Staphylococcus aureus Cap5O has UDP-ManNAc dehydrogenase activity and is essential for capsule expression. Infect. Immun. 2001, 69:917-923.
31. Potempa M., Potempa J., Okroj M., Popadiak K., Eick S., Nguyen K.A., Riesbeck K., Blom A.M. Binding of complement inhibitor C4b-binding protein contributes to serum resistance of Porphyromonas gingivalis. J. Immunol. 2008, 181:5537-5544.
32. Rooijakkers S.H., Ruyken M., van Roon J., van Kessel K.P., van Strijp J.A., van Wamel W.J. Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell. Microbiol. 2006, 8:1282-1293.
33. Rooijakkers S.H., van Kessel K.P., van Strijp J.A. Staphylococcal innate immune evasion. Trends Microbiol. 2005, 13:596-601.
34. Sharp J.A., Cunnion K.M. Disruption of the alternative pathway convertase occurs at the staphylococcal surface via the acquisition of factor H by Staphylococcus aureus. Mol. Immunol. 2011, 48:683-690.
35. Shevchenko A., Tomas H., Havlis J., Olsen J.V., Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat. Protoc. 2006, 1:2856-2860.
36. van Hal S.J., Paterson D.L. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 2011, 55:405-410.
37. van Wamel W.J., Rooijakkers S.H., Ruyken M., van Kessel K.P., van Strijp J.A. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on beta-hemolysin-converting bacteriophages. J. Bacteriol. 2006, 188:1310-1315.
38. Wooster D.G., Maruvada R., Blom A.M., Prasadarao N.V. Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation. Immunology 2006, 117:482-493.
39. Young T.P., Maas L., Thorp A.W., Brown L. Etiology of septic arthritis in children: an update for the new millennium. Am. J. Emerg. Med. 2011, 29:899-902.